Why carry out this study?
|
Subjects with skin of color (SoC) are frequently underrepresented in clinical trials, and SoC photographs are generally underrepresented in dermatology. |
This case series illustrates five subjects covering Fitzpatrick skin phototypes III, IV, V, and VI treated with trifarotene 0.005% cream in combination with 120 mg oral doxycycline with modified polymer coating for severe facial acne vulgaris (AV) for 12 weeks or with trifarotene 0.005% cream used as monotherapy for moderate facial and truncal AV for 24 weeks. |
What was learned from the study?
|
Trifarotene 0.005% cream, with or without oral doxycycline, demonstrates favorable efficacy and safety for treating moderate or severe AV in subjects with skin phototypes III–VI. |
Open Access 22.08.2022 | Case Series
Trifarotene 0.005% Cream in the Treatment of Facial and Truncal Acne Vulgaris in Patients with Skin of Color: a Case Series
Erschienen in: Dermatology and Therapy | Ausgabe 9/2022